This application of the Toledo Community Clinical Oncology Program (TCCOP) seeks funding for continuation of its ongoing clinical trials program. TCCOP has grown to a twelve institution regional consortium since 1982, when it was first funded. The catchment area encompasses a population of 1.2 million people in over a 6000 square mile area. Over the past four years of CCOP IV, 454 patients have been enrolled in treatments and 245 in cancer control studies. Strengths of the TCCOP remain a history of an impressive accrual track record; stability of experienced data management staff; dedicated physician participation; leadership in scientific activities of cooperative groups (NCCTG, ECOG, NSABP, RTOG, UMCC); increasing minority participation in resear5chl continuous improvement of data quality and efficiency; and a well established infrastructure to conduct clinical trials. Citizens in the community, realizing the importance of research, have increasingly participated in chemoprevention trials, with 99 BCPT subjects and 220 in PCPT. The STAR Trial is anticipated to enroll at least 240 participants.
The aims of this application include more strategies to increase accrual being implemented through more intense attention to screening; expansion of resources for recruitment to clinical trials; developing standards of excellence in research programs; and progress in developing more efficient data management systems. Finally, TCCOP foresees a continuous commitment of support and resources in this community for a highly successful clinical treatment and cancer control/chemoprevention research program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035415-19
Application #
6512461
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
Minasian, Lori M
Project Start
1983-09-15
Project End
2005-05-31
Budget Start
2002-06-05
Budget End
2003-05-31
Support Year
19
Fiscal Year
2002
Total Cost
$513,159
Indirect Cost
Name
Toledo Community Hospital Oncology Prog
Department
Type
DUNS #
City
Toledo
State
OH
Country
United States
Zip Code
43617
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7

Showing the most recent 10 out of 130 publications